LBI 0996
Alternative Names: LBI-0996Latest Information Update: 25 Jan 2022
At a glance
- Originator Luminus Biosciences
- Class Antineoplastics
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 30 Dec 2021 LBI 0996 is available for licensing as of 30 Dec 2021. https://www.luminusbiosciences.com/
- 30 Dec 2021 Preclinical trials in Breast cancer in USA (unspecified route) (Luminus Biosciences pipeline, December 2021)
- 30 Dec 2021 Luminus Biosciences plans clinical trial in Solid tumours by 2023 (Luminus Biosciences pipeline, December 2021)